Publication: Azacitidine versus decitabine in patients with refractory anemia with excess blast-results of multicenter study
dc.contributor.coauthor | Salim, Ozan | |
dc.contributor.coauthor | Toptas, Tayfur | |
dc.contributor.coauthor | Avsar, Esin | |
dc.contributor.coauthor | Yucel, Orhan Kemal | |
dc.contributor.coauthor | Geduk, Ayfer | |
dc.contributor.coauthor | Mehtap, Ozgur | |
dc.contributor.coauthor | Tombak, Anil | |
dc.contributor.coauthor | Tiftik, Eyup Naci | |
dc.contributor.coauthor | Deveci, Burak | |
dc.contributor.coauthor | Kurtoglu, Erdal | |
dc.contributor.coauthor | Kara, Osman | |
dc.contributor.coauthor | Atagunduz, Isik Kaygusuz | |
dc.contributor.coauthor | Tuglular, Tulin Firatli | |
dc.contributor.coauthor | Undar, Levent | |
dc.contributor.department | School of Medicine | |
dc.contributor.department | KUH (Koç University Hospital) | |
dc.contributor.kuauthor | Ferhanoğlu, Ahmet Burhan | |
dc.contributor.kuauthor | Öztürk, Erman | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.contributor.schoolcollegeinstitute | KUH (KOÇ UNIVERSITY HOSPITAL) | |
dc.date.accessioned | 2024-11-09T23:23:30Z | |
dc.date.issued | 2016 | |
dc.description.abstract | The present study aimed to compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndrome (MDS). A total of 88 patients diagnosed with refractory anemia with excess blast (RAEB) treated with azacitidine (n = 57) or decitabine (n = 31) were evaluated. Comparisons between azacitidine and decitabine groups were performed in the whole cohort, and in a 1:1 propensity score-matched cohort in order to reduce the simple selection bias. Patients who received azacitidine or decitabine had comparable overall response rates in both the unmatched (49.1% vs. 64.5%, p = 0.166) and the propensity-matched cohorts (52% vs. 68%, p = 0.248). The cumulative incidence of AML transformation at one year was comparable between azacitidine and decitabine in the unmatched (24.0% vs. 31.3%, p = 0.26) and in the propensity-matched cohorts (18.7% vs. 31.5%, p = 0.11). There was no difference in terms of transfusion requirement, febrile neutropenia episodes or the need for antifungal use during the treatment cycles in the propensity-matched cohort. The median overall survival was 20.4 months for azacitidine and 16.8 months for decitabine (p = 0.59). Finally, we found that at least a four-cycle treatment with any HMA was a favorable factor. In conclusion, both azacitidine and decitabine have similar efficacy and toxicity profiles in the treatment of MDS-RAEB. | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 45 | |
dc.identifier.doi | 10.1016/j.leukres.2016.04.003 | |
dc.identifier.issn | 0145-2126 | |
dc.identifier.quartile | Q3 | |
dc.identifier.scopus | 2-s2.0-84963808224 | |
dc.identifier.uri | https://doi.org/10.1016/j.leukres.2016.04.003 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/11257 | |
dc.keywords | Azacitidine | |
dc.keywords | Comparison | |
dc.keywords | Decitabine | |
dc.keywords | MDS | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartof | Leukemia Research | |
dc.subject | Hematology | |
dc.subject | Oncology | |
dc.subject | Cancer research | |
dc.title | Azacitidine versus decitabine in patients with refractory anemia with excess blast-results of multicenter study | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Öztürk, Erman | |
local.contributor.kuauthor | Ferhanoğlu, Ahmet Burhan | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication | f91d21f0-6b13-46ce-939a-db68e4c8d2ab | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication | 055775c9-9efe-43ec-814f-f6d771fa6dee | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |